These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15680586)

  • 1. Assessment of chemical libraries for their druggability.
    Sirois S; Hatzakis G; Wei D; Du Q; Chou KC
    Comput Biol Chem; 2005 Feb; 29(1):55-67. PubMed ID: 15680586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pursuing the leadlikeness concept in pharmaceutical research.
    Hann MM; Oprea TI
    Curr Opin Chem Biol; 2004 Jun; 8(3):255-63. PubMed ID: 15183323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consideration of molecular weight during compound selection in virtual target-based database screening.
    Pan Y; Huang N; Cho S; MacKerell AD
    J Chem Inf Comput Sci; 2003; 43(1):267-72. PubMed ID: 12546562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers.
    Chuprina A; Lukin O; Demoiseaux R; Buzko A; Shivanyuk A
    J Chem Inf Model; 2010 Apr; 50(4):470-9. PubMed ID: 20297844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual high-throughput screening of molecular databases.
    Seifert MH; Kraus J; Kramer B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):298-307. PubMed ID: 17554856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13.
    Blum LC; Reymond JL
    J Am Chem Soc; 2009 Jul; 131(25):8732-3. PubMed ID: 19505099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening for R-groups, including predicted pIC50 contributions, within large structural databases, using Topomer CoMFA.
    Cramer RD; Cruz P; Stahl G; Curtiss WC; Campbell B; Masek BB; Soltanshahi F
    J Chem Inf Model; 2008 Nov; 48(11):2180-95. PubMed ID: 18956863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in compound database preparation--"hidden" impact on virtual screening results.
    Knox AJ; Meegan MJ; Carta G; Lloyd DG
    J Chem Inf Model; 2005; 45(6):1908-19. PubMed ID: 16309298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A web-based platform for virtual screening.
    Watson P; Verdonk M; Hartshorn MJ
    J Mol Graph Model; 2003 Sep; 22(1):71-82. PubMed ID: 12798392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds.
    Axerio-Cilies P; Castañeda IP; Mirza A; Reynisson J
    Eur J Med Chem; 2009 Mar; 44(3):1128-34. PubMed ID: 18692938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in computer-aided drug design.
    Song CM; Lim SJ; Tong JC
    Brief Bioinform; 2009 Sep; 10(5):579-91. PubMed ID: 19433475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico screening of drug databases for TSE inhibitors.
    Lorenzen S; Dunkel M; Preissner R
    Biosystems; 2005 May; 80(2):117-22. PubMed ID: 15823410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the scaffold diversity of screening libraries.
    Krier M; Bret G; Rognan D
    J Chem Inf Model; 2006; 46(2):512-24. PubMed ID: 16562979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deriving knowledge through data mining high-throughput screening data.
    Diller DJ; Hobbs DW
    J Med Chem; 2004 Dec; 47(25):6373-83. PubMed ID: 15566306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of a generally applicable method to estimate retrieval of active molecules for similarity searching using fingerprints.
    Vogt M; Bajorath J
    ChemMedChem; 2007 Sep; 2(9):1311-20. PubMed ID: 17562536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites.
    Schmidtke P; Barril X
    J Med Chem; 2010 Aug; 53(15):5858-67. PubMed ID: 20684613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW; Murcko MA
    J Med Chem; 1996 Jul; 39(15):2887-93. PubMed ID: 8709122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leadlikeness and structural diversity of synthetic screening libraries.
    Verheij HJ
    Mol Divers; 2006 Aug; 10(3):377-88. PubMed ID: 17031539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SeleX-CS: a new consensus scoring algorithm for hit discovery and lead optimization.
    Bar-Haim S; Aharon A; Ben-Moshe T; Marantz Y; Senderowitz H
    J Chem Inf Model; 2009 Mar; 49(3):623-33. PubMed ID: 19231809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction methods and databases within chemoinformatics: emphasis on drugs and drug candidates.
    Jónsdóttir SO; Jørgensen FS; Brunak S
    Bioinformatics; 2005 May; 21(10):2145-60. PubMed ID: 15713739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.